Alladapt Immunotherapeutics
Menlo Park
About Alladapt Immunotherapeutics
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $229.0M
- Last round: Debt Financing (Aug 2022)
- Website: alladapt.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/alladapt-immunotherapeutics-95634 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.